The HIV research beat rolls ever onward, and this week's selection of featured studies from peer-reviewed journals strikes a varied and eclectic rhythm. Here's what has our brains humming this week -- that is, outside of all the blaring headlines you've likely seen about a new case of HIV remission and other important findings presented at CROI 2019:
- Efavirenz/tenofovir/emtricitabine (Atripla) may be just as effective when taken every other day as it is when taken daily.
- Hospitalized people with HIV -- especially marginalized people -- all too often fail to fill their antiretroviral prescriptions after discharge.
- As the U.S. vows to end its HIV epidemic by 2030, its progress against UNAIDS targets is mixed.
- Clustering -- and HIV coinfection -- was extremely common in hepatitis C outbreaks within a major French city.
Get those fingers tapping, and let's scroll through each of these four studies in more detail. To beat HIV, you have to follow the science!